Author name: Leonardo Arias

  El calzado deportivo moderno dejó de ser solo “una zapatilla cómoda”. Hoy es un sistema: materiales que reaccionan al impacto, estructuras que guían el movimiento, tejidos que regulan temperatura y diseños que buscan una sensación espec&iacute …

On the heels of several big buys, Merck still has eyes for M&A—particularly in the oncology, immunology and cardiometabolic spaces—as the quest continues for a candidate that can top Keytruda.

The insurer plans to say goodbye to the ACA exchanges after this year, and is exploring a potential sale of its controversial claims review subsidiary. Both businesses were more trouble than they were worth, executives said.

Foundayo became available on April 9 and has already reached 20,000 patients as Eli Lilly builds its marketing machine for the weight loss pill.

After two decades at Medtronic, Weidman will join Teleflex as the medtech company reshapes its portfolio.

After delaying a late-stage readout last year due to “irregularities” at certain study sites, pivotal data for Bristol Myers Squibb’s Cobenfy appear set to arrive later this year.

UniQure plans to submit AMT-130 to the U.K.’s Medicines and Healthcare products Regulatory Agency in the third quarter of 2026 based on Phase 1/2 data showing a 75% slowing of disease—the same data the FDA has deemed unacceptable for a biologics license application.

Healthcare organizations are struggling to navigate the compliance landscape amid a pullback in federal enforcement, a wave of state legislation and emerging voluntary initiatives, experts say.

Eli Lilly’s $19.8 billion revenue for the first quarter could have been higher if not for declining prices for key medicines like Zepbound, Mounjaro and Taltz.

Amylin drugs have become the next big thing in obesity. Eli Lilly CEO David Ricks, understandably, thinks his rivals don’t have a chance for one key reason.